Friday, November 24, 2017
Health

Three women blinded by unapproved stem cell 'treatment' at Florida clinic

RECOMMENDED READING


Three women with macular degeneration became permanently blind after undergoing an unproven stem-cell treatment touted as a clinical trial at a South Florida clinic. Medical experts said the episode raises questions about whether the government and doctors are doing enough to protect patients from the dangers of unapproved therapies.

The episode, described Wednesday in an article in the New England Journal of Medicine, represents one of the most egregious examples of patient injury involving a stem-cell clinic. These facilities have sprung up by the hundreds across the country over the past several years. Many offer supposed experimental treatments for ailments ranging from hip problems to autism to ALS.

Of special concern, said Jeffrey Goldberg, professor of ophthalmology at the Stanford University School of Medicine and one of the authors of the report, was the clinic's ability to list its study on ClinicalTrials.gov, a comprehensive database of clinical trials run by the National Institutes of Health. At least one of the patients — and maybe more — believed that she was taking part in a government-sanctioned study, he said.

Goldberg called the incident a "wake-up call across the spectrum" — for patients, physicians and government regulators. "Surely," he said, "it's an opportunity for the FDA to increase patient safety for these unapproved clinical trials."

RELATED COVERAGE: Tampa stem cell clinic is long on promises, not evidence

Thomas Albini, a University of Miami ophthalmologist and another one of the authors, said that he and his colleagues at the Bascom Palmer Eye Institute had treated two of the patients for severe complications in 2015, shortly after they had undergone the stem-cell procedures at a clinic in Sunrise. The severe complications included detached retinas, hemorrhages and vision loss.

"It's a disaster," Albini said, noting that the patients, before the stem-cell treatments, had only moderate vision loss. "Buyer beware: These stem-cell clinics that function in this very unregulated way are doing procedures that are not approved . . . and they can be quite dangerous."

The NEJM article did not identify the clinic or the patients, but its listing on the ClinicalTrials.gov website shows the sponsor as Bioheart Inc., also known as U.S. Stem Cell Inc., and says that the study was "withdrawn" before patients were enrolled. The clinic still has other stem-cell studies listed on the site, including for chronic obstructive pulmonary disease and degenerative disc disease.

RELATED COVERAGE: Desperate families turn to unproven stem cell treatment

Repeated calls to U.S. Stem Cell and to Kirstin Comella, who is listed as the chief scientific officer, have not been returned. In a NPR story last year, Comella said that two of the clinic's patients had suffered detached retinas following treatments, prompting the clinic to stop doing eye procedures.

According to Florida court filings, two of the patients involved, ages 72 and 78 at the time, sued the clinic and some individuals involved in the procedures. Their attorney, Andrew Yaffa of Coral Gables, said that the case "was resolved to the mutual satisfaction of the parties" but that neither he nor his clients could comment beyond that. The third patient was an 88-year-old Oklahoma resident who sought medical help a week after the stem-cell procedure at the Dean McGee Eye Institute in Oklahoma City.

Albini said the eye damage could have been the result of contamination during preparation of the stem cells. He also said it was possible that the stem cells could have changed into cells that are associated with scarring. Even if the solution had been prepared correctly, he said, there's no evidence that it could have helped restore the patients' vision.

Albini said the three patients paid $5,000 each for the stem-cell procedure, which involved conducting mini-liposuction procedures to remove fat from the abdominal area, isolating the stem cells from the fat and injecting those cells directly into eyes. Charging the patients was a "red flag," he said, that this was not a traditional clinical trial. A second was treating both eyes at the same time, rather than seeing how one eye responded before treating the other.

Age-related macular degeneration is the leading cause of vision loss in people older than 75 in the United States. While researchers are making "tremendous" progress using stem cells to treat the disease, the field requires careful study with meticulously designed trials, the authors of the paper said. The FDA has approved only a few stem-cell therapies, mostly for blood disorders.

The proliferation of stem-cell clinics — there are more than 570 of them, according to a study published last year — has ignited a fierce debate among physicians, patients and scientists about how they should be regulated. FDA rules allow the use of patients' own stem cells for treatments, without agency approval, but only if the procedures meet stringent conditions. The stem cells, for example, cannot be more than "minimally manipulated" and must be intended for the original function. That would not typically include using stem cells from fat to repair eye cells.

Albini said that the FDA had started an investigation into the case but a spokeswoman said the agency does not discuss potential or ongoing investigations. She added that consumers are encouraged to contact the FDA and state authorities to report any potentially illegal or harmful activity related to stem-cell-based products. The FDA has issued several drafts of guidance for the stem-cell industry to try to outline its thinking on the matter, but the documents have not been finalized, and many clinic operators oppose FDA regulation.

Paul Knoepfler, a stem-cell scientist at the University of California at Davis who is a frequent critic of the clinics, said he didn't understand why the FDA and the NIH have not moved more aggressively to ensure patient safety.

"It's puzzling and concerning," he said. He said that allowing the clinics to list their trials on ClinicalTrials.gov is "almost like a form of advertising for products that don't have FDA approval. That's really problematic."

In a statement, the NIH said that the information on ClinicalTrials.gov is provided by study sponsors and that posting on the site doesn't reflect endorsement by the NIH, which doesn't independently verify the scientific validity of the trial. It also said that every study includes links to an NIH disclaimer. "However, we agree that such caveats need to be clearer to all users and we will be adding a more prominent disclaimer in the future."

Comments
Revenge may not be so sweet after all

Revenge may not be so sweet after all

Jennifer Breheny Wallaceo the Washington PostA colleague steals your idea and then undermines you in front of the boss. It’s human nature to want revenge. But will getting even make you feel better in the long run?People are motivated to seek revenge...
Published: 11/24/17
Big Tobacco’s anti-smoking ads begin after decade of delay

Big Tobacco’s anti-smoking ads begin after decade of delay

WASHINGTON — Decades after they were banned from the airwaves, Big Tobacco companies return to prime-time television this weekend — but not by choice. Under court order, the tobacco industry for the first time will be forced to advertise the deadly, ...
Published: 11/21/17

Owning dogs may be great for your heart and lower risk of death, study finds

Dog ownership correlates with lower rates of mortality and some fatal diseases, particularly cardiovascular disease, a study published this past week concluded.The study in the journal Scientific Reports found that canine ownership was associated wit...
Published: 11/19/17
New shingles vaccine touted as a breakthrough for older adults

New shingles vaccine touted as a breakthrough for older adults

Medical researchers and government health policymakers, a cautious lot, normally take pains to keep expectations modest when they’re discussing some new finding or treatment.They warn about studies’ limitations. They point out what isn’t known. They ...
Published: 11/17/17
BayCare’s HealthHub breaks ground behind Valrico shopping center

BayCare’s HealthHub breaks ground behind Valrico shopping center

VALRICO — Health care officials broke ground Thursday on the long anticipated HealthHub at Bloomingdale, which will bring about 150 jobs to an area that’s experiencing tremendous growth and provide patients with the latest in technological care.A pro...
Published: 11/16/17
Updated: 11/19/17
In Tampa Bay and elsewhere, early numbers show record sign-ups for Obamacare

In Tampa Bay and elsewhere, early numbers show record sign-ups for Obamacare

Despite the budget cuts, the attempts to repeal and replace, and reports of sharp rises in premiums, Floridians and other Americans are signing up for health insurance under the Affordable Care Act at record rates this year.Enrollment has surged 47 p...
Published: 11/16/17
Updated: 11/17/17
Study: Mental quickness exercises can lower risk of dementia

Study: Mental quickness exercises can lower risk of dementia

Where did I leave my keys?As we age, it can take longer to answer a question like that.Humans begin to lose cognitive ability at age 25. Dementia, or the decline of memory most commonly seen in aging adults, takes hold early on and is gradual, but ac...
Published: 11/16/17
Making a list: holiday gift ideas for the water warrior, runner, fit foodie ...

Making a list: holiday gift ideas for the water warrior, runner, fit foodie ...

Given Santa’s legendary girth, one could justifiably question his ability to choose suitable gifts for the fitness-focused folks on his "nice" list. Dasher, Dancer and Prancer (all clearly more inclined to stay active) are always there to offer some ...
Published: 11/22/17
Mayo Clinic Q&A: gangrene causes and prevention; irregular bleeding

Mayo Clinic Q&A: gangrene causes and prevention; irregular bleeding

PEOPLE WITH DIABETES, PERIPHERAL ARTERY DISEASE AT INCREASED RISK OF GANGRENEI have heard that a stubbed toe can lead to gangrene in some individuals. Is that true? What are the signs of gangrene, and how can it be avoided?Gangrene, which refers to t...
Published: 11/15/17
Updated: 11/22/17
Blood pressure of 130 is the new ‘high,’ according to update of guidelines

Blood pressure of 130 is the new ‘high,’ according to update of guidelines

The nation’s heart experts tightened the guidelines for high blood pressure Monday, a change that will sharply increase the number of U.S. adults considered hypertensive in the hope that they, and their doctors, will address the deadly condition earl...
Published: 11/13/17